Vishwas Seshadri

Vishwas Seshadri (chief executive) discloses dealings in Abeona Therapeutics Inc. to SEC (Form 4). In total, 32 filings cover trades dated from 1 June 2021 to 29 September 2026.

Both buying and selling appear: 3 purchases worth €189k, against 12 sales worth €1.9M. The totals exclude 2 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 17 share grants. In 2026 alone, the filings show no purchases and 6 sales.

Half of the purchases are above €77k and half below. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 29 September 2026: an open-market sale of €89k, in Abeona Therapeutics Inc. The latest purchase dates back some time: it was published 902 days ago, on 29 April 2024. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.